# A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

> **NCT06271252** · PHASE1 · RECRUITING · sponsor: **OriCell Therapeutics Co., Ltd.** · enrollment: 81 (estimated)

## Conditions studied

- Neoplasms, Plasma Cell
- Neoplasms by Histologic Type
- Neoplasms
- Hemostatic Disorders
- Vascular Diseases
- Cardiovascular Diseases
- Paraproteinemias
- Blood Protein Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Immune System Diseases
- Multiple Myeloma

## Interventions

- **DRUG:** OriCAR-017

## Key facts

- **NCT ID:** NCT06271252
- **Lead sponsor:** OriCell Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-03
- **Primary completion:** 2026-12-12
- **Final completion:** 2028-04-12
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06271252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06271252, "A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06271252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*